Skip to main content
SpringerLink
Log in

Rejection

  • Chapter
Surgery

  • 328 Accesses

Abstract

The mammalian immune system is specialized for the discrimination between self and nonself. The appearance of new macromolecules (or antigens) normally signifies a threat, such as an infection or malignant tumor. In these settings, the prompt destruction of antigen-bearing cells is a valuable adaptation. Unfortunately, the same defense mechanisms are also efficiently invoked by the clinical transplantation of potentially lifesaving organs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Calne RY WD, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978;2:1323–1327.

    Article  PubMed  CAS  Google Scholar 

  2. Fung JJ, Starzl TE. FK506 in solid organ transplantation. Ther Drug Monit 1995;17:592–595.

    Article  PubMed  CAS  Google Scholar 

  3. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983;309:809–815.

    Google Scholar 

  4. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994;344:423–428.

    Google Scholar 

  5. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994;331:1110–1115.

    Google Scholar 

  6. Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. Transpllnt 1994;7(suppl 1):S247–S251.

    Google Scholar 

  7. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996;62:900–905.

    Article  PubMed  CAS  Google Scholar 

  8. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002;2:157–166.

    Google Scholar 

  9. Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician’s perspective. Liver Transpl 2004;10:577–583.

    Article  PubMed  Google Scholar 

  10. Pape L, Ehrich JH, Offner G. Advantages of cyclosporin A using 2-h levels in pediatric kidney transplantation. Pediatr Nephrol 2004;19:1035–1038.

    Article  PubMed  Google Scholar 

  11. Morton JM, Aboyoun CL, Malouf MA, Plit ML, Glanville AR. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant 2004;23:1035–1039.

    Article  PubMed  Google Scholar 

  12. Thomson AW. The immunosuppressive macrolides FK-506 and rapamycin. Immunol Lett 1991;29:105–111.

    Article  PubMed  CAS  Google Scholar 

  13. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998;66:1040–1046.

    Article  PubMed  CAS  Google Scholar 

  14. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036–1042.

    Article  PubMed  CAS  Google Scholar 

  15. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194–202.

    Article  PubMed  CAS  Google Scholar 

  16. Guilbeau JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002;36:1391–1395.

    Article  PubMed  Google Scholar 

  17. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002;74:804–808.

    Article  PubMed  CAS  Google Scholar 

  18. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a 3-year phase n, randomized, multicenter, open-label study. Transplantation 2004;78:1332–1340.

    Article  PubMed  CAS  Google Scholar 

  19. Sollinger HW, Belzer FO, Deierhoi MH, et al. RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 1992;216:513–518; discussion 8–9.

    Article  PubMed  CAS  Google Scholar 

  20. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995;345:1321–1325.

    Google Scholar 

  21. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225–232.

    Article  PubMed  CAS  Google Scholar 

  22. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996;61:1029–1037.

    Google Scholar 

  23. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004;18:485–492.

    Article  PubMed  Google Scholar 

  24. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004;4:231–236.

    Article  PubMed  CAS  Google Scholar 

  25. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996;348:643–648.

    Article  PubMed  CAS  Google Scholar 

  26. Grewal HP, Thistlethwaite JR Jr, Loss GE, et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. Transplant Proc 1998;30:1378–1379.

    Article  PubMed  CAS  Google Scholar 

  27. Wiland AM, Fink JC, Weir MR, et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004;77:422–425.

    Article  PubMed  Google Scholar 

  28. ter Meulen CG, van Riemsdijk I, Hene RJ, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004;4:803–810.

    Article  PubMed  CAS  Google Scholar 

  29. Pageaux GP, Calmus Y, Boillot O, et al. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 2004;10:1454–1460.

    Article  PubMed  Google Scholar 

  30. Hocker B, John U, Plank C, et al. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after 4 years. Transplantation 2004;78:228–234.

    Article  PubMed  Google Scholar 

  31. Kaufman DB, Iii GW, Bruce DS, et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003;3:855–864.

    Article  PubMed  Google Scholar 

  32. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48–56.

    Article  PubMed  CAS  Google Scholar 

  33. Zuckermann AO, Grimm M, Czerny M, et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 2000;69:1890–1898.

    Article  PubMed  CAS  Google Scholar 

  34. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 1985;313:337–342.

    Google Scholar 

  35. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation 2003;75:1512–1517.

    Article  PubMed  CAS  Google Scholar 

  36. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68:1613–1616.

    Article  PubMed  CAS  Google Scholar 

  37. Friend PJ, Hale G, Waldmann H, et al. Campath-1M—prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation 1989;48:248–253.

    Article  PubMed  CAS  Google Scholar 

  38. Abou-Jaoude MM, Ghantous I, Almawi WY. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. Mol Immunol 2003;39:1083–1088.

    Article  PubMed  CAS  Google Scholar 

  39. Ault BH, Honaker MR, Osama Gaber A, et al. Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 2002;17:815–818.

    Article  PubMed  Google Scholar 

  40. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus non-induction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001;72:1050–1055.

    Article  PubMed  CAS  Google Scholar 

  41. Hesse UJ, Troisi R, Jacobs B, et al. A single center’s clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin Transplant 2000;14(4 pt 1):340–344.

    Article  PubMed  CAS  Google Scholar 

  42. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999;116:127–133.

    Article  PubMed  CAS  Google Scholar 

  43. Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998;13:711–715.

    Article  PubMed  CAS  Google Scholar 

  44. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997;64:1701–1705.

    Article  PubMed  CAS  Google Scholar 

  45. Waldmann TA, O’Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998;10:507–512.

    Article  PubMed  CAS  Google Scholar 

  46. Millis JM, Cronin DC, Newell KA, et al. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. Transplant Proc 1997;29:1549.

    Article  PubMed  CAS  Google Scholar 

  47. Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996;62:594–599.

    Article  PubMed  CAS  Google Scholar 

  48. Woodle ES, Cronin D, Newell KA, et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation 1996;62:906–910.

    Article  PubMed  CAS  Google Scholar 

  49. Shimizu T, Tokiwa M, Yamaguchi Y. A case of acute antidonor antibody-mediated humoral rejection after renal transplantation with specific consideration of serial graft biopsy histology. Clin Transplant 2002;16(suppl 8):62–67.

    Article  PubMed  Google Scholar 

  50. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001;71:652–658.

    Article  PubMed  CAS  Google Scholar 

  51. Aichberger C, Nussbaumer W, Rosmanith P, et al. Plasmapheresis for the treatment of acute vascular rejection in renal transplantation. Transplant Proc 1997;29:169–170.

    Article  PubMed  CAS  Google Scholar 

  52. Berglin E, Kjellstrom C, Mantovani V, Stelin G, Svalander C, Wiklund L. Plasmapheresis as a rescue therapy to resolve cardiac rejection with vasculitis and severe heart failure. A report of five cases. Transpl Int 1995;8:382–387.

    Article  PubMed  CAS  Google Scholar 

  53. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998;352:1285.

    Article  PubMed  CAS  Google Scholar 

  54. Aranda JM Jr, Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab] therapy for acute cardiac humoral rejection: a case report. Transplantation 2002;73:907–910.

    Article  PubMed  Google Scholar 

  55. Garrett HE Jr, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002;74:1240–1242.

    Article  PubMed  Google Scholar 

  56. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996–1001.

    Article  PubMed  CAS  Google Scholar 

  57. Solez K. International standardization of criteria for histologic diagnosis of chronic rejection in renal allografts. Clin Transplant 1994;8(3 pt 2):345–350.

    PubMed  CAS  Google Scholar 

  58. Matas AJ, Burke JF Jr, DeVault GA Jr, Monaco A, Pirsch JD. Chronic rejection. J Am Soc Nephrol 1994;4(8 suppl):S23–S29.

    PubMed  CAS  Google Scholar 

  59. Tesi RJ, Elkhammas EA, Henry ML, Ferguson RM. OKT3 for primary therapy of the first rejection episode in kidney transplants. Transplantation 1993;55:1023–1029.

    Article  PubMed  CAS  Google Scholar 

  60. Ashraf S, Parrott NR, Dyer P, Roberts I, Johnson RW. Clinical response and temporal patterns of acute cellular rejection: relationship to chronic transplant nephropathy. Transpl Int 1998;11(suppl 1):S5–S9.

    PubMed  Google Scholar 

  61. Klintmalm GB, Nery JR, Husberg BS, Gonwa TA, Tillery GW. Rejection in liver transplantation. Hepatology 1989;10:978–985.

    Article  PubMed  CAS  Google Scholar 

  62. Mor E, Gonwa TA, Husberg BS, Goldstein RM, Klintmalm GB. Late-onset acute rejection in orthotopic liver transplantation-associated risk factors and outcome. Transplantation 1992;54:821–824.

    Article  PubMed  CAS  Google Scholar 

  63. Dousset B, Conti F, Cherruau B, et al. Is acute rejection deleterious to long-term liver allograft function? J Hepatol 1998;29:660–668.

    Article  PubMed  CAS  Google Scholar 

  64. Snover DC, Freese DK, Sharp HL, Bloomer JR, Najarian JS, Ascher NL. Liver allograft rejection. An analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol 1987;11:1–10.

    Article  PubMed  CAS  Google Scholar 

  65. McDiarmid SV, Klintmalm GB, Busuttil RW. FK506 conversion for intractable rejection of the liver allograft. Transpl Int 1993;6:305–312.

    Article  PubMed  CAS  Google Scholar 

  66. Grimbert P, Baron C, Fruchaud G, et al. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients. Transpl Int 2002;15:550–555.

    Article  PubMed  CAS  Google Scholar 

  67. Tran HT, Acharya MK, McKay DB, et al. Avoidance of cyclo-sporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000;11:1903–1909.

    PubMed  CAS  Google Scholar 

  68. Stegall MD, Larson TS, Prieto M, et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplant Proc 2003;35(3 suppl):125S–127S.

    Article  PubMed  CAS  Google Scholar 

  69. Schrama YC, Joles JA, van Tol A, Boer P, Koomans HA, Hene RJ. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000;69:376–383.

    Article  PubMed  CAS  Google Scholar 

  70. Kotb M, Russell WC, Hathaway DK, Gaber LW, Gaber AO. The use of positive B cell flow cytometry crossmatch in predicting rejection among renal transplant recipients. Clin Transplant 1999;13(1 pt 2):83–89.

    Article  PubMed  CAS  Google Scholar 

  71. Pelletier RP, Orosz CG, Adams PW, et al. Clinical and economic impact of flow cytometry crossmatching in primary cadaveric kidney and simultaneous pancreas-kidney transplant recipients. Transplantation 1997;63:1639–1645.

    Article  PubMed  CAS  Google Scholar 

  72. Christiaans MH, Overhof R, ten Haaft A, Nieman F, van Hooff JP, van den Berg-Loonen EM. No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically well-documented renal allograft recipients. Transplantation 1996;62:1341–1347.

    Article  PubMed  CAS  Google Scholar 

  73. Mahoney RJ, Norman DJ, Colombe BW, Garovoy MR, Leeber DA. Identification of high-and low-risk second kidney grafts. Transplantation 1996;61:1349–1355.

    Article  PubMed  CAS  Google Scholar 

  74. Scornik JC, Brunson ME, Schaub B, Howard RJ, Pfaff WW. The crossmatch in renal transplantation. Evaluation of flow cytometry as a replacement for standard cytotoxicity. Transplantation 1994;57:621–625.

    Article  PubMed  CAS  Google Scholar 

  75. Ogura K, Terasaki PI, Johnson C, et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 1993;56:294–298.

    Article  PubMed  CAS  Google Scholar 

  76. Ogura K, Terasaki PI, Koyama H, Chia J, Imagawa DK, Busuttil RW. High 1-month liver graft failure rates in flow cytometry crossmatch-positive recipients. Clin Transplant 1994;8(2 pt 1):111–115.

    PubMed  CAS  Google Scholar 

  77. Bishay ES, Cook DJ, Starling RC, et al. The clinical significance of flow cytometry crossmatching in heart transplantation. Eur J Cardiothorac Surg 2000;17:362–369.

    Article  PubMed  CAS  Google Scholar 

  78. Chow FY, Polkinghorne K, Saunder A, Kerr PG, Atkins RC, Chadban SJ. Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. Nephrology (Carlton) 2003;8:212–216.

    Article  PubMed  CAS  Google Scholar 

  79. Mocarquer A, Pinto V, Buckel E, et al. of the Simulect Multi-center Study Group of Chile. Basiliximab: efficacy and tolerabil-ity in adults and children. Transplant Proc 2003;35:2518–2519.

    Article  PubMed  CAS  Google Scholar 

  80. Martin Garcia D, Martin Gago J, Mendiluce A, et al. Tacrolimus-basiliximab versus cyclosporine-basiliximab in renal transplantation “de novo”: acute rejection and complications. Transplant Proc 2003;35:1694–1696.

    Article  PubMed  CAS  Google Scholar 

  81. Kode R, Fa K, Chowdhury S, et al. Basiliximab plus low-dose cyclosporin versus OKT3 for induction immunosuppression following renal transplantation. Clin Transplant 2003;17:369–376.

    Article  PubMed  Google Scholar 

  82. Sheashaa HA, Bakr MA, Ismail AM, Sobh MA, Ghoneim MA. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol 2003;16:393–398.

    PubMed  CAS  Google Scholar 

  83. Lawen JG, Davies EA, Mourad G, et al. of the Simulect International Study Group. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophe-nolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003;75:37–43.

    Article  PubMed  CAS  Google Scholar 

  84. Offner G, Broyer M, Niaudet P, et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation 2002;74:961–966.

    Article  PubMed  CAS  Google Scholar 

  85. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48–56.

    Article  PubMed  CAS  Google Scholar 

  86. Neuhaus P, Clavien PA, Kittur D, et al. of the CHIC 304 International Liver Study Group. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132–142.

    Article  PubMed  Google Scholar 

  87. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123–131.

    Article  PubMed  Google Scholar 

  88. Sollinger H, Kaplan B, Pescovitz MD, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001;72:1915–1919.

    Article  PubMed  CAS  Google Scholar 

  89. Ponticelli C, Yussim A, Cambi V, et al. of the Simulect Phase IV Study Group. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001;72:1261–1267.

    Article  PubMed  CAS  Google Scholar 

  90. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999;67:276–284.

    Article  PubMed  CAS  Google Scholar 

  91. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997;350:1193–1198.

    Article  PubMed  CAS  Google Scholar 

  92. Pescovitz MD, Bumgardner G, Gaston RS, et al. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant 2003;17:511–517.

    Article  PubMed  Google Scholar 

  93. Abou-Jaoude MM, Ghantous I, Najm R, Afif C, Almawi WY. Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients. Transplant Proc 2003;35:2731–2732.

    Article  PubMed  CAS  Google Scholar 

  94. Heffron TG, Pillen T, Smallwood GA, Welch D, Oakley B, Romero R. Pediatric liver transplantation with daclizumab induction. Transplantation 2003;75:2040–2043.

    Article  PubMed  CAS  Google Scholar 

  95. Kuypers DR, Vanrenterghem YF. Monoclonal antibodies in renal transplantation: old and new. Nephrol Dial Transplant 2004;19:297–300.

    Article  PubMed  CAS  Google Scholar 

  96. Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003;75:1260–1266.

    Article  PubMed  CAS  Google Scholar 

  97. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002;2:568–573.

    Article  PubMed  CAS  Google Scholar 

  98. Stratta RJ, Alloway RR, Hodge E, Lo A; Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis. Transplant Proc 2002;34:1903–1905.

    Article  PubMed  CAS  Google Scholar 

  99. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001;20:1282–1290.

    Article  PubMed  CAS  Google Scholar 

  100. Bumgardner GL, Hardie I, Johnson RW, et al. of the Phase III Daclizumab Study Group. Results of 3-year phase HI clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001;72:839–845.

    Article  PubMed  CAS  Google Scholar 

  101. Ekberg H, Backman L, Tufveson G, Tyden G, Nashan B, Vin-centi F. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int 2000;13:151–159.

    Article  PubMed  CAS  Google Scholar 

  102. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000;342:613–619.

    Article  PubMed  CAS  Google Scholar 

  103. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999;67:110–115.

    Article  PubMed  CAS  Google Scholar 

  104. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase HI trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc 1998;30:2155–2158.

    Article  PubMed  CAS  Google Scholar 

  105. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-IH) and low-dose tacrolimus immunosuppression in adult liver transplantation [erratum in Transplantation 2004;78:489]. Transplantation 2004;77:1209–1214.

    Article  PubMed  CAS  Google Scholar 

  106. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-IH). Transplantation 2003;76:120–129.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The University of Chicago Medical Center, Chicago, IL, USA

    J. Richard Thistlethwaite MD, PhD (Professor and President)

  2. Medical Staff, The University of Chicago Medical Center, Chicago, IL, USA

    J. Richard Thistlethwaite MD, PhD (Professor and President)

  3. Department of Transplant Surgery, LifeLink Healthcare Institute, Tampa, FL, USA

    David Bruce MD, FACS (Transplant Surgeon)

Authors
  1. J. Richard Thistlethwaite MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Bruce MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Stanford University Medical Center, Stanford, CA, USA

    Jeffrey A. Norton MD, FACS (Robert L. and Mary Ellenburg Professor, Chief) (Robert L. and Mary Ellenburg Professor, Chief)

  2. Divisions of Surgical Oncology and General Surgery, Department of Surgery, Stanford University Medical Center, Stanford, CA, USA

    Jeffrey A. Norton MD, FACS (Robert L. and Mary Ellenburg Professor, Chief) (Robert L. and Mary Ellenburg Professor, Chief)

  3. Departments of Surgery and Public Health, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA

    Philip S. Barie MD, MBA, FCCM, FACS (Professor, Chief) (Professor, Chief)

  4. Division of Critical Care and Trauma, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA

    Philip S. Barie MD, MBA, FCCM, FACS (Professor, Chief) (Professor, Chief)

  5. Departments of Surgery and Immunology, Duke University Medical Center, Durham, NC, USA

    R. Randal Bollinger MD, PhD, FACS (Professor) (Professor)

  6. Division of Surgical Oncology, Department of Surgery, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA

    Alfred E. Chang MD, FACS (Chief, Hugh Cabot Professor of Surgery) (Chief, Hugh Cabot Professor of Surgery)

  7. Department of Surgery, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA

    Stephen F. Lowry MD, MBA, FACS (Professor and Chairman) (Professor and Chairman)

  8. Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Stephen F. Lowry MD, MBA, FACS (Professor and Chairman) (Professor and Chairman)

  9. Department of Surgery, The University of Utah, Salt Lake City, UT, USA

    Sean J. Mulvihill MD, FACS (Professor and Chair, Senior Director of Clinical Affairs) (Professor and Chair, Senior Director of Clinical Affairs)

  10. Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA

    Sean J. Mulvihill MD, FACS (Professor and Chair, Senior Director of Clinical Affairs) (Professor and Chair, Senior Director of Clinical Affairs)

  11. Departments of Cardiothoracic Surgery and Surgery, New York University Medical Center, New York, NY, USA

    Harvey I. Pass MD, FACS (Professor) (Professor)

  12. Radiology, and Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA

    Robert W. Thompson MD, FACS (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research) (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research)

  13. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

    Robert W. Thompson MD, FACS (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research) (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Thistlethwaite, J.R., Bruce, D. (2008). Rejection. In: Norton, J.A., et al. Surgery. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68113-9_82

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-68113-9_82

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-30800-5

  • Online ISBN: 978-0-387-68113-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation